TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37051919

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1107
Study: 37051976

Group type: EXPERIMENTAL
Intervention: Hip mobilisations along with strengthening exercises of hip and conventional knee exercises
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Strengthening exercises of hip along with conventional knee interventional exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional knee exercises only
Number of subjects: 66
Study: 37051980

Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan (Group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Not fasting during Ramadan (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 (Group A)
Number of subjects: 52
Study: 37052067

Group type: EXPERIMENTAL
Intervention: Head elevation
Number of subjects: 174

Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 174
Study: 37052073

Group type: EXPERIMENTAL
Intervention: Group 1 (5 to 10 kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 2 (10 to 20 kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 3 (20 to 40 kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 37052108

Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37052120

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 0
Study: 37052133

Group type: EXPERIMENTAL
Intervention: Individualized strategy
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Restrictive strategy
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Liberal strategy
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: All strategies
Number of subjects: 1182
Study: 37052216

Group type: COMPARATOR
Intervention: Indoor solar lighting systems
Number of subjects: 80
Study: 37052316

Group type: EXPERIMENTAL
Intervention: Public healthcare system during the COVID-19 pandemic (2020)
Number of subjects: 36559

Group type: COMPARATOR
Intervention: Private healthcare system during the COVID-19 pandemic (2020)
Number of subjects: 36559

Group type: COMPARATOR
Intervention: Pre-pandemic period (2019)
Number of subjects: 36559
Study: 37052557

Group type: EXPERIMENTAL
Intervention: MHO group
Number of subjects: 120

Group type: COMPARATOR
Intervention: MUHO group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Increased body mass index
Number of subjects: 120
Study: 37052562

Group type: EXPERIMENTAL
Intervention: QFR (Fractional Flow Reserve derived from invasive coronary angiography)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Invasive FFR (control)
Number of subjects: 250
Study: 37052578

Group type: EXPERIMENTAL
Intervention: ProFit score (intervention for assessing prosthetic fit and alignment)
Number of subjects: 113
Study: 37052667

Group type: EXPERIMENTAL
Intervention: Optical correction with or without patching
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glasses with patching
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glasses alone
Number of subjects: 32
Study: 37052688

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 37052803

Group type: EXPERIMENTAL
Intervention: CBD10 (10 mg/kg/day)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: CBD20 (20 mg/kg/day)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 37052821

Group type: EXPERIMENTAL
Intervention: sintilimab + modified FOLFIRINOX (mFFX)
Number of subjects: 110

Group type: COMPARATOR
Intervention: modified FOLFIRINOX (mFFX)
Number of subjects: 110
Study: 37052913

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ultrasonography plus CEUS
Number of subjects: 172

Group type: COMPARATOR
Intervention: Scintigraphy
Number of subjects: 172
Study: 37052929

Group type: EXPERIMENTAL
Intervention: Self-fitting OTC hearing aid with remote support
Number of subjects: 68

Group type: COMPARATOR
Intervention: Audiologist-fitted hearing aid
Number of subjects: 68
Study: 37052965

Group type: EXPERIMENTAL
Intervention: Avelumab plus carboplatin and paclitaxel (n=63)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (n=62)
Number of subjects: 125
Study: 37053050

Group type: EXPERIMENTAL
Intervention: High-calorie feeding
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 22
Study: 37053246

Group type: EXPERIMENTAL
Intervention: Sequential bilateral accelerated theta burst stimulation (aTBS) administered as 3 sessions daily for 10 days, with 1,800 pulses delivered continuously to the right DLPFC and intermittently to the left DLPFC.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TBS treatment administered as 3 sessions daily for 10 days.
Number of subjects: 0
Study: 37053376

Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding patients
Number of subjects: 116
Study: 37053413

Group type: EXPERIMENTAL
Intervention: PACE intervention (mobile-based application with personalized content and cognitive behavioral skills training)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 485
Study: 37053429

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 49
Study: 37053529

Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard insulin delivery)
Number of subjects: 0
Study: 37053531

Group type: EXPERIMENTAL
Intervention: Capillary hemoglobin A1c (HbA1c) collection
Number of subjects: 258

Group type: COMPARATOR
Intervention: Venous hemoglobin A1c (HbA1c) measurement
Number of subjects: 258
Study: 37053535

Group type: EXPERIMENTAL
Intervention: Trametinib (MEK1/2 inhibitor)
Number of subjects: 50
Study: 37054503

Group type: EXPERIMENTAL
Intervention: Tyrosine receptor kinase inhibitor (TRKi) treatment in patients with simple genomics NMT.
Number of subjects: 188

Group type: COMPARATOR
Intervention: First-generation TRKi treatment in patients with complex genomics NMT.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Median metastatic survival in patients with complex genomics NMT.
Number of subjects: 188
Study: 37054556

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus platinum chemotherapy (GC) + bevacizumab
Number of subjects: 34

Group type: COMPARATOR
Intervention: Gemcitabine plus platinum chemotherapy (GC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 34
Study: 37054807

Group type: EXPERIMENTAL
Intervention: Interactive online childbirth education platform (Birthly) combined with usual prenatal education
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual prenatal education alone
Number of subjects: 90
Study: 37054888

Group type: EXPERIMENTAL
Intervention: β-glucan 1.5 g
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: β-glucan 3 g
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: β-glucan 6 g
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: All β-glucan groups
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 263
Study: 37054897

Group type: EXPERIMENTAL
Intervention: Online mindfulness-based intervention (MBI)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 219
Study: 37054898

Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Programme plus Information and Communication Technologies (LMP + ICTs)
Number of subjects: 188
Study: 37054908

Group type: EXPERIMENTAL
Intervention: Coronary angiography-derived IMR (caIMR)
Number of subjects: 113
Study: 37055189

Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 60
Study: 37055198

Group type: EXPERIMENTAL
Intervention: 6 L NC 100% oxygen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care (no respiratory support)
Number of subjects: 120
Study: 37055201

Group type: EXPERIMENTAL
Intervention: UC plus access to Stand Down (App)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: UC plus Peer-Supported Stand Down (PSSD) - four peer-led phone sessions over the initial 8 weeks
Number of subjects: 274

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 274
Study: 37055203

Group type: EXPERIMENTAL
Intervention: Goat milk formula (whey:casein ratio of 20:80, 50% milk fat from whole goat milk)
Number of subjects: 2296

Group type: COMPARATOR
Intervention: Cow milk formula (control, whey:casein ratio of 60:40, 100% lipids from vegetable oils)
Number of subjects: 2296

Group type: EXPERIMENTAL
Intervention: Goat milk formula
Number of subjects: 2296

Group type: COMPARATOR
Intervention: Cow milk formula
Number of subjects: 2296
Study: 37055205

Group type: EXPERIMENTAL
Intervention: SIESTA in combination with treatment as usual (TAU) for ADHD
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIESTA
Number of subjects: 0
Study: 37055207

Group type: EXPERIMENTAL
Intervention: SOC+L (Leflunomide 100 mg/day for 3 days followed by 10-20 mg/day for 7 days)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: SOC+L
Number of subjects: 214

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 214
Study: 37055213

Group type: EXPERIMENTAL
Intervention: Femom (NIFECG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cCTG monitoring
Number of subjects: 0
Study: 37055214

Group type: EXPERIMENTAL
Intervention: HABIT-ILE (50 hours over 2 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual motor activity and regular rehabilitation
Number of subjects: 48
Study: 37055215

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched peers without NE
Number of subjects: 0
Study: 37055276

Group type: EXPERIMENTAL
Intervention: Combined pectoralis II and serratus anterior plane blocks (ultrasound-guided, using a mixture of plain and liposomal bupivacaine)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Routine analgesia
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Combined pectoralis II and serratus anterior plane blocks
Number of subjects: 194
Study: 37055279

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 6 cycles of gemcitabine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with 3 cycles of gemcitabine followed by chemoradiation therapy (CRT) and another 3 cycles of gemcitabine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CA19-9 response to initial adjuvant gemcitabine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Postoperative CA19-9 levels
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CA19-9 response
Number of subjects: 125
Study: 37055459

Group type: EXPERIMENTAL
Intervention: Machine learning architecture utilizing mobile sensing data and social networks for emotion prediction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social network integration in affect prediction
Number of subjects: 0
Study: 37055566

Group type: EXPERIMENTAL
Intervention: Salt substitute (62.5% NaCl and 25% KCl)
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Usual salt
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Restricted salt supply
Number of subjects: 1612
Study: 37055640

Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA (ctDNA) detection and profiling after curative intent therapy
Number of subjects: 0
Study: 37055702

Group type: EXPERIMENTAL
Intervention: Air-Q Blocker
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: All three devices
Number of subjects: 150
Study: 37055724

Group type: EXPERIMENTAL
Intervention: Gugging Swallowing Screen (GUSS)-ICU
Number of subjects: 45
Study: 37055730

Group type: EXPERIMENTAL
Intervention: Screening questionnaire for early identification of risk for excessive GWG
Number of subjects: 1790
Study: 37055818

Group type: EXPERIMENTAL
Intervention: Inversion strength test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eversion strength test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single Leg Stance (SLS) test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single Leg Hop for Distance (SLHD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Side Hop test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Limb Symmetry Index (LSI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sensitivity of the test battery
Number of subjects: 20
Study: 37055910

Group type: EXPERIMENTAL
Intervention: Hyaluronan synthesis inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care approaches (including ACE inhibitors, ARBs, SGLT2 inhibitors, finerenone, GLP-1 receptor agonists)
Number of subjects: 0
Study: 37056360

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 54
Study: 37056363

Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation (TPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham TPS
Number of subjects: 30
Study: 37056765

Group type: EXPERIMENTAL
Intervention: Radiotherapy of 24 Gy/3 fractions/3-10 days plus liposomal irinotecan (80mg/m) followed by camrelizumab and anti-angiogenic treatment
Number of subjects: 60
Study: 37057191

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ocrelizumab and Fingolimod
Number of subjects: 40
Study: 37057394

Group type: EXPERIMENTAL
Intervention: Anti-TG2 antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 37057827

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1706
Study: 37057905

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 8304
Study: 37058047

Group type: COMPARATOR
Intervention: Brushing, dental floss and tongue scraper
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brushing, dental floss and aPDT applied to the dorsum and middle third of the tongue
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brushing, dental floss and probiotics
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, aPDT and probiotics
Number of subjects: 52
Study: 37058173

Group type: EXPERIMENTAL
Intervention: Rituximab-chemotherapy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 328
Study: 37058234

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T with abiraterone (STAMP trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T with enzalutamide (STRIDE trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential administration of sipuleucel-T and ARTAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent administration of sipuleucel-T and ARTAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0
Study: 37058302

Group type: EXPERIMENTAL
Intervention: Smart System of Disease Management (SSDM) group
Number of subjects: 2197

Group type: COMPARATOR
Intervention: Conventional care control group
Number of subjects: 2197
Study: 37058346

Group type: EXPERIMENTAL
Intervention: Vet Flexiquit
Number of subjects: 49

Group type: COMPARATOR
Intervention: SmokefreeVET
Number of subjects: 49
Study: 37058414

Group type: EXPERIMENTAL
Intervention: QST setup with manual tests performed by a human tester
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: QST setup with automated tests performed by a robot and orally guided by a human tester
Number of subjects: 179

Group type: COMPARATOR
Intervention: QST setup with automated tests performed solely by a robot without social interaction
Number of subjects: 179
Study: 37058426

Group type: EXPERIMENTAL
Intervention: quit for a bit
Number of subjects: 98

Group type: COMPARATOR
Intervention: quit for good
Number of subjects: 98
Study: 37058475

Group type: EXPERIMENTAL
Intervention: Day-8 blood MRD measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day-22 blood MRD measurement
Number of subjects: 0
Study: 37058479

Group type: EXPERIMENTAL
Intervention: Vaccination (2 doses)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Omicron variant infection
Number of subjects: 64
Study: 37058600

Group type: COMPARATOR
Intervention: PUFA (polyunsaturated fatty acids)
Number of subjects: 2374
Study: 37058687

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37058726

Group type: EXPERIMENTAL
Intervention: Any opioid administration
Number of subjects: 680

Group type: COMPARATOR
Intervention: Lowest opioid dose group
Number of subjects: 680

Group type: COMPARATOR
Intervention: Third opioid dose group
Number of subjects: 680
Study: 37058788

Group type: EXPERIMENTAL
Intervention: Mobocertinib
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 114
Study: 37059239

Group type: EXPERIMENTAL
Intervention: Branched/fenestrated endovascular aortic repair
Number of subjects: 1681
Study: 37059261

Group type: EXPERIMENTAL
Intervention: Mind Guide (mobile mindfulness app)
Number of subjects: 16
Study: 37059327

Group type: EXPERIMENTAL
Intervention: S201086/GLPG1972 75 mg
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: S201086/GLPG1972 150 mg
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: S201086/GLPG1972 300 mg
Number of subjects: 932

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 932
Study: 37059391

Group type: EXPERIMENTAL
Intervention: Smoking cessation (SC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 0
Study: 37059395

Group type: EXPERIMENTAL
Intervention: Iron-biofortified potato meals
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonbiofortified potato meals
Number of subjects: 28
Study: 37059507

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 7 mg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 10 mg/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 37059508

Group type: EXPERIMENTAL
Intervention: Zilucoplan 0.3 mg/kg once daily by self-injection for 12 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Zilucoplan
Number of subjects: 174
Study: 37059696

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 37059702

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/day
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg/day
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg/day
Number of subjects: 2524
Study: 37059834

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 282
Study: 37060015

Group type: EXPERIMENTAL
Intervention: Screened patients with PGVs (n=124)
Number of subjects: 6660

Group type: EXPERIMENTAL
Intervention: Screened patients without PGVs (n=776)
Number of subjects: 6660

Group type: COMPARATOR
Intervention: Non-screened patients
Number of subjects: 6660

Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (TNBC) cases
Number of subjects: 6660

Group type: EXPERIMENTAL
Intervention: ER+/HER2- cases
Number of subjects: 6660
Study: 37060023

Group type: EXPERIMENTAL
Intervention: mPATH™-CRC program with a 'high touch' implementation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: mPATH™-CRC program with a 'low touch' implementation strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mPATH™-CRC program (post-implementation cohort)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-implementation cohort
Number of subjects: 0
Study: 37060024

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEIs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Angiotensin-receptor blockers (ARBs)
Number of subjects: 100
Study: 37060040

Group type: EXPERIMENTAL
Intervention: Arthroscopic assisted distal radius cancellous chips graft reconstruction
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open iliac crest cancellous graft reconstruction
Number of subjects: 88
Study: 37060049

Group type: EXPERIMENTAL
Intervention: Heart rate (HR) monitoring
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HR-informed changes in potentially painful care procedures
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Communication through HR for 6 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pre-intervention HR measurement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Changes in procedures for identified painful situations
Number of subjects: 38
Study: 37060053

Group type: EXPERIMENTAL
Intervention: Pragmatic digital health obesity treatment intervention
Number of subjects: 18
Study: 37060055

Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles (50, 75, and 100 mg/kg) added to standard concomitant radio-chemotherapy (temozolomide and radiotherapy)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles with radiochemotherapy
Number of subjects: 66
Study: 37060176

Group type: EXPERIMENTAL
Intervention: OBP-301 (oncolytic adenovirus)
Number of subjects: 20
Study: 37060236

Group type: EXPERIMENTAL
Intervention: Fixed Starting Dose (FSD) of niraparib, 300 mg once daily
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Individualized Starting Dose (ISD) of niraparib, 200 mg once daily for patients with baseline body weight < 77 kg or baseline platelet count < 150,000/µL; 300 mg once daily for all other patients
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Individualized Starting Dose (ISD) of niraparib
Number of subjects: 733

Group type: COMPARATOR
Intervention: Fixed Starting Dose (FSD) of niraparib
Number of subjects: 733